PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment
Pipeline Therapeutics, a clinical-stage biopharmaceutical firm specializing in precision neuroregeneration, has announced the initiation of dosing for the Phase 1 clinical trial of PIPE-791 in ... Read More
PIPE-505 : Pipeline Therapeutics initiates phase 1/2a SNHL trial
Pipeline Therapeutics has initiated a phase 1/2a trial of PIPE-505, which is a small molecule gamma secretase inhibitor (GSI), in patients who have sensorineural hearing ... Read More